thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
== Career == Principal Scientist SCIEX - 1980-2005 Associate Professor (CLTA) at the University of Toronto, first in the Institute of Biomaterials and Biomedical Engineering (2005–2008) and then in Chemistry 2008–2013. President DVS Sciences 2004 - 2015 (acquired by Fluidigm in 2014) Adjunct Professor at York University in the Department of Chemistry 2015–2018
== History == LG CNS was founded in 1987 as System Technology Management (STM), a 50:50 joint venture between LG and Electronic Data Systems. In 1995, the company was renamed LG-EDS System as part of LG Group's corporate identity integration project. After LG acquired all of EDS's shares, the company changed its name to LG CNS in January 2002. In 2019, LG sold a 35% stake in LG CNS to Macquarie Group for 1 trillion won (US$865 million). This sale occurred amid growing criticism of South Korea's chaebols for allegedly benefiting founding families by over-relying on outsourcing contracts and directing work to subsidiaries and affiliates. Macquarie acquired the stake in LG CNS with the condition that LG would list the company by April 2025. As a result, LG CNS debuted on the market in February 2025. On January 28, 2026, Macquarie divested its remaining 8.3% stake in the company through a block deal.
Yet the presumed causes of the uprising did not translate uniformly into actual rebellion. The rebel leaders proclaimed no coherent articles of faith that presaged a new political system. Crucially, many regions of India—including the Punjab, the Madras and Bombay presidencies—did not join the rebellion, thereby ensuring its ultimate defeat; neither did the Bengali intelligentsia, nor the major princely states. After the rebellion was suppressed in 1858, the East India Company was disbanded, and the British government assumed direct administration of India. Proclaiming a unitary state and a gradual but limited British-style parliamentary system, the new rulers also protected princes and landed gentry as a feudal safeguard against future unrest. In the decades following, a more organised public life gradually emerged across India, eventually leading to the founding of the Indian National Congress in 1885. Rapid commercialisation of agriculture in the second half of the 19th century brought severe economic setbacks, leaving many small farmers dependent on the uncertainties of distant markets. This period saw a rise in the frequency of large-scale famines; moreover, despite the risks of infrastructure development being borne by Indian taxpayers, little industrial employment was generated for the local population. However, commercial cropping, especially in the newly canal-irrigated Punjab, did increase food production for internal consumption.
Lynn Bry is a physician, anaerobic microbiologist, and microbial geneticist at Brigham & Women's Hospital, and Harvard Medical School. She has created multiple multi-institutional platforms to support scientific, clinical and educational activities, including the MadSci Network, Crimson prospective collection resource, Massachusetts Host-Microbiome Center, and Partners Healthcare-wide Pathogen Genomic Surveillance Program. She has also founded or co-founded successful start-up companies including iSpecimen and ConsortiaTX. She was awarded her MD and a PhD in Molecular Microbiology and Pathogenesis from Washington University School of Medicine. Her research studies host-microbiome interactions and their application to develop new therapeutics for human disease. She has authored or co-authored >70 peer-reviewed articles and book chapters, including original papers in Science detailing a molecular model of host-microbial cross-talk in the small intestine, and in Nature Medicine demonstrate therapeutic use of defined commensal microbes to reverse food allergies. Bry teaches medical school courses and is also a lecturer and mentor for the Project Success Program at Harvard Medical School. While at Washington University, Bry founded and became Executive Director of The Madsci Network, an Ask-A-Scientist service based on the World Wide Web. The service involves more than 900 globally situated volunteer scientists who field questions from the general public and from students in kindergarten through the 12th grade.
Sources: en.wikipedia.org
== History == Naltrexone was first synthesized in 1963 by Metossian at Endo Laboratories, a small pharmaceutical company in New York City. It was characterized by Blumberg, Dayton, and Wolf in 1965 and was found to be an orally active, long-acting, and very potent opioid antagonist. The drug showed advantages over earlier opioid antagonists such as cyclazocine, nalorphine, and naloxone, including its oral activity, a long duration of action allowing for once-daily administration, and a lack of dysphoria, and was selected for further development. It was patented by Endo Laboratories in 1967 under the developmental code name EN-1639A and Endo Laboratories was acquired by DuPont in 1969. Clinical trials for opioid dependence began in 1973, and a developmental collaboration of DuPont with the National Institute on Drug Abuse for this indication started the next year in 1974. The drug was approved by the FDA for the oral treatment of opioid dependence in 1984, with the brand name Trexan, and for the oral treatment of alcohol dependence in 1995, when the brand name was changed by DuPont to Revia. A depot formulation for intramuscular injection was approved by the FDA under the brand name Vivitrol for alcohol dependence in 2006 and opioid dependence in 2010.
== Legality == In the United States, a letter from Terrence L. Boos, Ph.D., Chief Drug & Chemical Evaluation Section Diversion Control Division at the DEA shows they consider nor-BNI a Schedule II substance as a derivative of noroxymorphone due to its broad definition in the CSA covering "derivatives". However, no court cases are known to exist for its prosecution and it is possible this could be challenged in court.
=== Other medications === Bupropion, topiramate, metformin, zonisamide, and amphetamine are sometimes used off-label for weight loss. The usefulness of certain drugs depends upon the comorbidities present. Metformin is preferred in overweight diabetics and for those gaining weight, as it may lead to mild weight loss in comparison to sulfonylureas or insulin. The thiazolidinediones, on the other hand, may cause weight gain, but decrease central obesity. Diabetics also achieve modest weight loss with fluoxetine and orlistat over 12–57 weeks. Sibutramine (Meridia), which acts in the brain to inhibit deactivation of the neurotransmitters, thereby decreasing appetite was withdrawn from the UK market in January 2010 and United States and Canadian markets in October 2010 due to cardiovascular concerns. In 2010 it was found that sibutramine increases the risk of heart attacks and strokes in people with a history of cardiovascular disease. Recombinant human leptin is very effective in those with obesity due to congenital complete leptin deficiency via decreasing energy intake and possibly increases energy expenditure. This condition is, however, rare and this treatment is not effective for inducing weight loss in the majority of people with obesity. It is being investigated to determine whether or not it helps with weight loss maintenance. Though hypothesized that supplementation of vitamin D may be an effective treatment for obesity, studies do not support this. There is also no strong evidence to recommend herbal medicines for weight loss.
Resting membrane potential The baseline electrical potential across the neuron's membrane when it is not actively sending signals, typically around –70 mV in neurons. Reticular formation A network of nuclei in the brainstem involved in regulating arousal, attention, sleep–wake cycles, and autonomic functions. Retina A thin layer of tissue at the back of the eye that contains photoreceptors and neurons responsible for detecting light and initiating visual processing. Retinotopy An orderly representation of the visual field maintained throughout the visual pathways, including the visual cortex. Retrograde amnesia A type of memory loss where individuals cannot recall past memories prior to a brain injury, while the ability to form new memories may be preserved. Retrograde transport The movement of materials from the axon terminal back to the cell body, typically via dynein motors. Used for recycling vesicles and transporting signals. Rett syndrome A rare neurodevelopmental disorder, primarily affecting females, caused by mutations in the MECP2 gene. Characterized by developmental regression, motor problems, and seizures. Reuptake The process by which neurotransmitters are reabsorbed by the presynaptic neuron after being released, terminating synaptic transmission. Reward system A group of brain structures involved in motivation, pleasure, and reinforcement. Includes the ventral tegmental area, nucleus accumbens, and prefrontal cortex. Rhinal cortex A region of the medial temporal lobe that plays a key role in memory and object recognition.
Kerry-Lynne Donna Findlay (born January 12, 1955) is a Canadian politician and lawyer who served as leader of the Conservative Party of British Columbia from May to September 2026. She had served as a member of Parliament (MP) for South Surrey—White Rock from 2019 to 2025 and Delta—Richmond East from 2011 to 2015 with the federal Conservative Party. Findlay was Associate Minister of National Defence in 2013, and Minister of National Revenue from 2013 to 2015 under Prime Minister Stephen Harper.
Sources: en.wikipedia.org
(Endogastric means the shell is curved so as the ventral or lower side is longitudinally concave (abdomen in); exogastric means the shell is curved so as the ventral side is longitudinally convex (abdomen out) allowing the funnel to be pointed backward beneath the shell.)
== History == In 2019, Hailey Rhode Bieber began conceptualizing a cosmetics brand and filed to trademark "Bieber Beauty". It was rejected, as her husband Justin Bieber had already trademarked the name in 2010. Bieber later launched rhode skin on June 15, 2022, alongside Lauren and Michael D. Ratner, choosing the name as a direct reference to her own middle name, Rhode, after her initial "Bieber Beauty" trademark application was rejected. Rhode was funded primarily by Bieber, with investment firm One Luxury Group as a strategic partner. Its core products at launch included the Peptide Glazing Fluid, Barrier Restore Cream and Peptide Lip Treatment. Within 11 days, Rhode had achieved $10 million in sales. One week following the launch, a fashion brand named Rhode co-founded by Purna Khatau and Phoebe Vickers filed a trademark infringement claim against Bieber, claiming her use of the name caused consumer confusion. A judge denied the motion "for a preliminary injunction without prejudice." In May 2025, Rhode announced it would be acquired by e.l.f. in a deal that consists of $800 million in cash and stock, with an additional $200 million based on future sales. The acquisition was completed in August. In April 2026, Rhode released the Rhode x The Biebers collaboration with Justin Bieber, introducing Spotwear hydrocolloid pimple patches alongside limited-edition versions of its Peptide Lip Treatment and Peptide Eye Prep.
=== Kidney damage === Lithium has been associated with several forms of kidney injury. It is estimated that impaired urinary concentrating ability is present in at least half of individuals on chronic lithium therapy, a condition called lithium-induced nephrogenic diabetes insipidus, or lithium-induced AVP resistance. This occurs because lithium competes with the antidiuretic hormone in the kidney and increases water output into the urine. Clearance of lithium by the kidneys is usually successful with certain diuretic medications, including amiloride and triamterene. Continued use of lithium can lead to more serious kidney damage in an aggravated form of nephrogenic diabetes insipidus. Lithium specifically inhibits function of the aquaporin-2 water channel, leading to impaired reabsorption of water, polyuria, polydipsia, significant hypernatremia, which can lead to CNS symptoms such as confusion, lethargy, and coma. Chronic kidney disease, otherwise known as chronic renal insufficiency (CRI), occurs in 1–5% of people after 10–20 years of lithium treatment. End-stage renal disease occurs in 0.53% of people treated with lithium versus 0.2% in the general population. Kidney harm can be mitigated by keeping the lithium dose as low as possible and dosing lithium once per day at night. Multiple daily doses are associated with more kidney damage. Dosing lithium once per day allows for long periods where the kidney is exposed to low levels of lithium, which minimizes kidney harm.
Icatibant, sold under the brand name Firazyr, is a medication for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults with C1-esterase-inhibitor deficiency. It is not effective in angioedema caused by medication from the ACE inhibitor class. It is a peptidomimetic consisting of ten amino acids, which is a selective and specific antagonist of bradykinin B2 receptors.
== Legacy == According to The Tuscaloosa News, by the "Great Depression, the ruins of the burned statehouse were dispersed or massed into a low mound with grass on top." In 1988, "a design committee, which included architectural historian Robert Mellown...began extensive historical and archaeological research...and drew up plans to create a ruin." A historical marker in the park commemorates the school's history. The University of Alabama has a collection of papers related to the school. A poem about the old capitol was published. The western end of the 4.5-mile Riverwalk begins at Capitol Park. Located at the South West Corner in the McGuire Strickland House since 1993 is The Capitol School. It is a private school serving students from 6 weeks through High school.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.